5、消化系统肿瘤消化系统肿瘤 (27).pdf
《5、消化系统肿瘤消化系统肿瘤 (27).pdf》由会员分享,可在线阅读,更多相关《5、消化系统肿瘤消化系统肿瘤 (27).pdf(6页珍藏版)》请在得力文库 - 分享文档赚钱的网站上搜索。
1、 Journal of Clinical Oncology List of Issues Volume 39,Issue 15_suppl Meeting Abstract|2021 ASCO Annual Meeting IGASTROINTESTINAL CANCERGASTROESOPHAGEAL,PANCREATIC,ANDHEPATOBILIARYGemox chemotherapy in combination withanti-PD1 antibody toripalimab and lenvatinibas first-line treatment for advancedRi
2、ghts&PermissionsOPTIONS&TOOLSExport CitationTrack CitationAdd To FavoritesADVERTISEMENTADADVERTISEMENTLog InSubmitE-AlertsCartOpenAthens/Shibboleth MENU Article Toolsintrahepatic cholangiocarcinoma:A phase 2clinical trial.Zhou Jian,Jia Fan,Guo-Ming Shi,Xiao-Yong Huang,Dong Wu,Guo-HuanYang,.Show More
3、Abstract Disclosures4094Background:The outcome of advancedintrahepatic cholangiocarcinoma(ICC)remainspoor with current gemcitabine-basedchemotherapy.This study is to evaluate the safetyand efficacy of anti-PD1 agent toripalimab,lenvatinib in combination with oxaliplatin andgemcitabine(Gemox)chemothe
4、rapy.Methods:Locally advanced or metastatic ICC patients(pts)were given 240 mg toripalimab Q3W viaintravenous(IV)infusion,8 mg lenvatinib QDorally,and 1g/m gemcitabine on Day 1 and Day 8,COMPANION ARTICLESNo companion articlesARTICLE CITATIONDOI:10.1200/JCO.2021.39.15_suppl.4094Journal of Clinical O
5、ncology 39,no.15_suppl(May 20,2021)4094-4094.Published online May 28,2021.WE RECOMMENDADVERTISEMENTEmployer:Merritt HawkinsApply for this job Employer:Potomac Oncology&HematologyApply for this job Hematology-Oncology OpportunityJust Outside of ChicagoRockford,Illinois N/AA reputable integrated healt
6、h system seekinga board-certified or board-eligiblehematologist-oncologist to join its team.Oncology&Hematology AssociatePositionRockville,Maryland Competitive SalaryThis position offers a competitive base salary,a comprehensive benefits package,exceptional productivity incentives,and apartnership t
7、rack.Hematology/Oncology-at the Beach inLow Tax Delaware!Delaware(US);Family-oriented resort area inbeautiful south coastal DelawareAbstractGemOx(Gemcitabine+Oxaliplatin)versus Gem(Gemcitabine)in nonresectable pancreaticadenocarcinoma:final results of theGERCOR/GISCAD Intergroup PhaseIIIC.Louvet et
8、al.,J Clin Oncol,2004Phase II study of gemcitabine,capecitabine and cisplatin in patientswith advanced pancreatic cancerH.M.Chang et al.,J Clin Oncol,2004Best Supportive Care Compared WithChemotherapy for Unresectable GallBladder Cancer:A RandomizedControlled StudyAtul Sharma et al.,J Clin Oncol,201
9、0and 85 mg/m oxaliplatin Q3W by IV for 6 cycles.The primary outcome was objective response rate(ORR),which was evaluated according to RECISTv1.1.Secondary outcomes included safety,progression-free survival(PFS)and overall survival(OS).Treatment would be terminated byconfirmed disease progression,una
10、cceptabletoxicity,or voluntary withdrawal.Whole exomesequencing was performed on available tumortissues and PD-L1 expression was determined byimmunohistochemistry staining.Results:FromMay 2019 to Oct 2019,30 pathologically-confirmedadvanced ICC pts with a mean age of 56.5(range,25-73)years,including
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 5、消化系统肿瘤消化系统肿瘤 27 消化系统 肿瘤 27
限制150内